180 related articles for article (PubMed ID: 34847292)
21. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
[TBL] [Abstract][Full Text] [Related]
22. A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.
Dahlbäck B; Tran S
J Thromb Haemost; 2022 May; 20(5):1146-1157. PubMed ID: 35247027
[TBL] [Abstract][Full Text] [Related]
23. Protein arginine deiminase 4 inactivates tissue factor pathway inhibitor-alpha by enzymatic modification of functional arginine residues.
Thomassen MCLGD; Bouwens BRC; Wichapong K; Suylen DP; Bouwman FG; Hackeng TM; Koenen RR
J Thromb Haemost; 2023 May; 21(5):1214-1226. PubMed ID: 36716968
[TBL] [Abstract][Full Text] [Related]
24. Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.
Reitsma SE; Holle LA; Bouck EG; Monroe DM; Mast AE; Burthem J; Bolton-Maggs PHB; Gidley GN; Wolberg AS
J Thromb Haemost; 2023 Mar; 21(3):467-479. PubMed ID: 36696199
[TBL] [Abstract][Full Text] [Related]
25. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.
Wood JP; Bunce MW; Maroney SA; Tracy PB; Camire RM; Mast AE
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17838-43. PubMed ID: 24127605
[TBL] [Abstract][Full Text] [Related]
26. Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.
Mast AE
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):9-14. PubMed ID: 26603155
[TBL] [Abstract][Full Text] [Related]
27. New insights into the biology of tissue factor pathway inhibitor.
Maroney SA; Mast AE
J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S200-7. PubMed ID: 26149025
[TBL] [Abstract][Full Text] [Related]
28. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.
Duckers C; Simioni P; Spiezia L; Radu C; Gavasso S; Rosing J; Castoldi E
Blood; 2008 Nov; 112(9):3615-23. PubMed ID: 18695002
[TBL] [Abstract][Full Text] [Related]
29. Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia.
Egan K; O'Connor H; Kevane B; Malone F; Lennon A; Al Zadjali A; Cooley S; Monteith C; Maguire P; Szklanna PB; Allen S; McCallion N; Ní Áinle F
Thromb Haemost; 2017 Jul; 117(8):1549-1557. PubMed ID: 28569919
[TBL] [Abstract][Full Text] [Related]
30. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.
Duckers C; Simioni P; Spiezia L; Radu C; Dabrilli P; Gavasso S; Rosing J; Castoldi E
Blood; 2010 Jan; 115(4):879-86. PubMed ID: 19861681
[TBL] [Abstract][Full Text] [Related]
31. Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short.
Dahlbäck B
J Thromb Haemost; 2023 Apr; 21(4):716-727. PubMed ID: 36746318
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of LDL-associated tissue factor pathway inhibitor.
Augustsson C; Hilden I; Petersen LC
Thromb Res; 2014 Jul; 134(1):132-7. PubMed ID: 24787991
[TBL] [Abstract][Full Text] [Related]
33. New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV-Short.
Dahlbäck B; Guo LJ; Zöller B; Tran S
J Thromb Haemost; 2019 Apr; 17(4):585-595. PubMed ID: 30740865
[TBL] [Abstract][Full Text] [Related]
34. Biology of tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Blood; 2014 May; 123(19):2934-43. PubMed ID: 24620349
[TBL] [Abstract][Full Text] [Related]
35. Thrombin generation abnormalities in Quebec platelet disorder.
Brunet JG; Sharma T; Tasneem S; Liang M; Wilson MD; Rivard GE; Hayward CPM
Int J Lab Hematol; 2020 Dec; 42(6):801-809. PubMed ID: 32761872
[TBL] [Abstract][Full Text] [Related]
36. Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S.
Ellery PER; Hilden I; Sejling K; Loftager M; Martinez ND; Maroney SA; Mast AE
Res Pract Thromb Haemost; 2018 Jan; 2(1):93-104. PubMed ID: 29354797
[TBL] [Abstract][Full Text] [Related]
37. Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI.
Puy C; Tucker EI; Ivanov IS; Gailani D; Smith SA; Morrissey JH; Gruber A; McCarty OJ
PLoS One; 2016; 11(10):e0165172. PubMed ID: 27764259
[TBL] [Abstract][Full Text] [Related]
38. Rethinking events in the haemostatic process: role of factor V and TFPI.
Camire RM
Haemophilia; 2016 Jul; 22 Suppl 5():3-8. PubMed ID: 27405668
[TBL] [Abstract][Full Text] [Related]
39. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function.
Cunha ML; Bakhtiari K; Peter J; Marquart JA; Meijers JC; Middeldorp S
Blood; 2015 Mar; 125(11):1822-5. PubMed ID: 25634741
[TBL] [Abstract][Full Text] [Related]
40. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.
Stavik B; Tinholt M; Sletten M; Skretting G; Sandset PM; Iversen N
J Hematol Oncol; 2013 Jan; 6():5. PubMed ID: 23320987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
